03:33 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
18:40 , Aug 8, 2018 |  BC Innovations  |  Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
22:18 , Aug 1, 2018 |  BC Extra  |  Company News

Management tracks: Hologic, Tricidia

Hologic Inc. (NASDAQ:HOLX) said Bob McMahon has departed as CFO to become CFO at Agilent Technologies Inc. (NYSE:A). The diagnostics company promoted Chief Accounting Officer Karleen Oberton to CFO. Metabolic acidosis play Tricida Inc. (NASDAQ:TCDA)...
19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Patient sample and mouse studies suggest gene editing of CD40L cDNA in autologous hematopoietic stem cells (HSCs) could help treat X-linked hyper-IgM syndrome (XHIM), which is caused by CD40L mutations. In patient-derived T...
18:48 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest an ANXA5-targeting, single-chain variable fragment (scFv)-based fusion protein could help treat stroke. The protein consists of an scFv derived from a mouse IgM antibody targeting ANXA5, which...
19:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Aridis, Shenzhen Hepalink form China JV

Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals Co. Ltd. -- to develop and gain regulatory approval of two of Aridis’ candidates, Salvecin...
19:55 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Patient sample, cell culture and macaque studies identified a combination of mAbs against EDII and EDIII that could help treat Zika infection. Screening of mAb clones derived from blood plasmablasts of a...
23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
19:50 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

NEJM publishes Phase II renal transplant data for Hansa's IdeS

Combined data from a pair of open-label Phase II trials showed that 24 of 25 highly human leukocyte antigen (HLA)-sensitized patients treated with IdeS from Hansa Medical AB (SSE:HMED) achieved a successful kidney transplantation. Data...